home All News open_in_new Full Article
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE
Theratechnologies presented PROMISE-US trial data at CROI 2025, demonstrating ibalizumab's efficacy and safety in reducing HIV RNA to undetectable levels in heavily treatment-experienced patients with multidrug-resistant HIV. The PROMISE-US registry study showed that patients treated with ibalizumab achieved similar rates of undetectable viral load as those on non-ibalizumab regimens, despite more severe HIV disease at baseline.
today 48 h. ago attach_file Other
attach_file
Economics
attach_file
Society
attach_file
Economics
attach_file
Events
attach_file
Other
attach_file
Transport
attach_file
Economics
attach_file
Politics
attach_file
Other
attach_file
Transport
attach_file
Other
attach_file
Transport
attach_file
Other
attach_file
Economics
ID: 948573956